Search Medical Condition
Please enter condition
Please choose location

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (321) clinical trials

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia. May be compensated for time and ...

Phase

The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type. Approximately 325 patients will be enrolled at approximately 50 centers in North America.

Phase

This study tests whether two investigational drugs called CAD106 and CNP520, administered separately, can delay and slow the progression of clinical symptoms associated with Alzheimer's Disease in participants at risk of developing clinical symptoms based on their age and genotype.   Other Details: https://clinicaltrials.gov/ct2/show/NCT02565511

Phase

Evaluate the efficacy of Lanabecestat in mild Alzheimer's Disease dementia   Other Details:  https://clinicaltrials.gov/ct2/show/study/NCT02783573

Phase

People with Schizophrenia are asked to participate in a research study being conducted by Zucker Hillside Hospital.

Phase N/A

The primary objective is to evaluate the effects of administration of neflamapimod (VX-745) for 24-weeks on immediate and delayed recall aspects of episodic memory, as assessed by the Hopkins Verbal Learning Test – Revised (HVLT-R) in subjects with mild Alzheimer’s disease (AD).

Phase

The purpose of this research study is to measure the effects of a study drug on body weight in young adults that have schizophrenia, schizophreniform or bipolar 1 disorder. This study will last approximately 20 weeks. There will be 11 study visits. Each visit lasts between 1 and 4 hours. ...

Phase N/A

The purpose of this study is to evaluate whether the investigational medication, JNJ-54861911, slows cognitive decline compared with placebo (inactive treatment) in individuals with generally normal memory and thinking ability but who are at risk for developing Alzheimer's dementia.  Study qualification and whether or not a potential study participant is ...

Phase

Long Term Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, or 12-AVR-131. Participants will be enrolled in the study for approximately 56 weeks (participants who have a follow-up visit 3 months after the last dose of treatment will be enrolled for approximately 64 weeks). Approximately 700 participants will be enrolled at approximately 135 ...

Phase